Semaglutide Dosing for Weight Loss
For weight loss in adults, start semaglutide subcutaneously at 0.25 mg once weekly and titrate monthly to a maximum maintenance dose of 2.4 mg weekly. 1
Specific Titration Schedule
The FDA-approved and guideline-recommended escalation protocol is:
- Week 1-4: 0.25 mg once weekly (starting dose)
- Week 5-8: 0.5 mg once weekly
- Week 9-12: 1.0 mg once weekly
- Week 13-16: 1.7 mg once weekly
- Week 17 onward: 2.4 mg once weekly (maintenance dose)
This monthly dose escalation is designed to minimize gastrointestinal side effects while achieving therapeutic efficacy 1, 2.
Expected Weight Loss Outcomes
At the 2.4 mg weekly maintenance dose:
- Mean weight reduction of 14.9-16.9% at 68 weeks 3, 1
- 86% of patients achieve ≥5% weight loss 4
- 69% achieve ≥10% weight loss 4
- 50% achieve ≥15% weight loss 4
Weight loss is sustained with continued treatment, with 16.7% mean weight reduction maintained at 2 years 1.
Critical Dosing Considerations
Long-term treatment is necessary. Discontinuation leads to significant weight regain—patients regained 11.6% of lost weight within 52 weeks after stopping 3. This is not a time-limited intervention but requires ongoing therapy for sustained benefit.
The 2.4 mg dose is superior to lower doses. While some real-world data show weight loss with 0.5-1.0 mg doses (7-9% at 24 weeks) 5, these results are substantially inferior to the 2.4 mg dose and should not be considered adequate for obesity treatment unless tolerability issues prevent escalation.
Formulation Options
Subcutaneous semaglutide 2.4 mg weekly is the FDA-approved formulation for obesity in adults (approved 2021) and adolescents ≥12 years (approved 2022) 1.
Oral semaglutide at 50 mg daily has shown comparable efficacy (15.1% weight loss at 68 weeks) in phase III trials but is not yet FDA-approved for obesity treatment 3, 1, 6. The oral formulation requires specific administration (taken on empty stomach with minimal water, 30 minutes before food) due to ~1% bioavailability versus 89% for subcutaneous 6.
Population-Specific Considerations
Patients with type 2 diabetes experience attenuated weight loss compared to those without diabetes. In the SURMOUNT-2 trial, weight reduction was lower in diabetic patients, and similar patterns were observed with semaglutide 1, 5. Expect approximately 7-8% weight loss versus 12-14% in non-diabetic patients at comparable doses 5.
East Asian populations show robust response, with 13.2% mean weight loss at 68 weeks with 2.4 mg weekly, along with 40% reduction in visceral fat area 7.
Cardiovascular Benefits
Beyond weight loss, semaglutide 2.4 mg provides 20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal MI, non-fatal stroke) in patients with established cardiovascular disease and obesity without diabetes, leading to FDA approval for secondary cardiovascular risk reduction 1.
Common Pitfalls to Avoid
Inadequate dose escalation: Real-world data shows nearly half of patients deviate from recommended monthly titration schedules 8. Stick to the protocol unless tolerability issues arise.
Stopping at lower maintenance doses: The 2.4 mg dose is the evidence-based target. Lower doses (0.5-1.0 mg) produce substantially less weight loss 1, 5.
Premature discontinuation: 46-48% of patients discontinue within 5 months in real-world practice 8. Address financial barriers (copayment strongly predicts discontinuation) and manage gastrointestinal side effects proactively.
Expecting sustained benefit after stopping: Weight regain is rapid and substantial upon discontinuation 3. Set expectations for long-term therapy from the outset.
Safety Profile
Gastrointestinal adverse events (nausea, diarrhea) are most common, occurring in 59-64% of patients, but are typically mild-to-moderate and transient 3, 7. These subside with continued treatment and are the primary reason for the gradual dose escalation.
Serious adverse events occur at modestly elevated rates (RR 1.33) compared to placebo 9, warranting appropriate patient selection and monitoring. Treatment discontinuation due to adverse events occurs in approximately 3-5% of patients 7.